Jun 2026 (Q2 FY26) — Aug 5, 2026
Schrodinger Q2 FY26 — Strong ACV Growth and Bunsen AI Co-Scientist Launch
Read the full callSchrodinger (SDGR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Schrodinger earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 58.9 | +7.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -70.5 | +26.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 6.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$22.6 −11.30% · −$2.88
Performance +9.7% 1Y
1Y: $20.61 on 15 Oct 2025 → $22.6. High $32.6 (5 Oct 2026), low $11.07 (30 Mar 2026).
- Previous close
- $25.48
- 52-week range
- $11.07 – $32.6
- One year
- +11.28%
Overview
- Symbol
- SDGR
- Sector
- Information Technology
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Schrodinger earnings calls (SDGR)
Financials
What the filings say
Net profit, year on year: +114% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 35 | 88 | 60 | 55 | 54 | 87 | 59 | 59 |
| Operating profit | -68 | -21 | -51 | -53 | -46 | -17 | -49 | -42 |
| Operating margin | −193.9% | −23.4% | −85.5% | −96.6% | −84.6% | −19.7% | −83.3% | −70.5% |
| Other income | 30 | -19 | -9 | 10 | 13 | 50 | -11 | 49 |
| Profit before tax | -38 | -39 | -60 | -43 | -33 | 33 | -60 | 7 |
| Tax rate | 0.2% | −2.5% | −0.1% | −0.7% | −0.5% | 1.4% | −0.7% | 18.7% |
| Net profit | -38 | -40 | -60 | -43 | -33 | 33 | -60 | 6 |
| EPS ($ per share) | -0.52 | — | -0.82 | -0.59 | -0.45 | — | -0.81 | 0.08 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 1 | — | — | — | — | — |
| Reserves | -105 | -130 | -230 | -379 | -338 | -526 | -629 |
| Total liabilities | 57 | 122 | 199 | 241 | 254 | 402 | 362 |
| Fixed assets | 6 | 5 | 10 | 14 | 23 | 24 | 19 |
| Investments | 60 | 440 | 456 | 361 | 308 | 205 | 165 |
| Total assets | 155 | 746 | 756 | 689 | 803 | 823 | 726 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -26 | 17 | -71 | -120 | -137 | -157 | 14 |
| Cash from investing | -54 | -382 | -17 | 90 | 193 | 149 | 58 |
| Cash from financing | 29 | 541 | 8 | 2 | 9 | 10 | 3 |
| Net cash flow | — | 176 | -80 | -28 | 65 | 2 | 75 |
| Capital expenditure | -2 | -3 | -7 | -8 | -13 | -7 | -1 |
| Free cash flow | -28 | 14 | -78 | -128 | -150 | -165 | 12 |
Insider filings
51 filings between Feb 9, 2026 and Sep 17, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$2.30M
20 sales by 7 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 24
- Award — granted as compensation
- 5
- Option exercise — converted options into shares
Also filed: 2 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Farid Ramy | — | $1.17M | Apr 17, 2026 |
| Akinsanya Karen | — | $972.0K | Sep 17, 2026 |
| Jain Rachit | — | $45.4K | Jul 16, 2026 |
| Abel Robert Lorne | — | $33.3K | Mar 4, 2026 |
| Lorton Kenneth Patrick | — | $28.5K | Mar 5, 2026 |
| Herman Jenny | — | $28.1K | Mar 6, 2026 |
| Tran Yvonne | — | $24.8K | Mar 5, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 17, 2026 | Akinsanya Karen See Remarks | Option exercise 10b5-1 plan | 31,599 | $137.1K |
| Sep 17, 2026 | Akinsanya Karen See Remarks | Sale 10b5-1 plan | 10,000 | $280.0K |
| Sep 17, 2026 | Akinsanya Karen See Remarks | Sale 10b5-1 plan | 21,599 | $648.0K |
| Jul 16, 2026 | Jain Rachit EVP & CFO | Sale 10b5-1 plan | 875 | $13.6K |
| Jun 26, 2026 | Friesner Richard Director | Gift | 679,373 | $0 |
| Jun 26, 2026 | Friesner Richard Director | Gift | 679,373 | $0 |
| Jun 22, 2026 | Kapeller-Libermann Rosana Director | Award | 8,141 | $0 |
| Jun 22, 2026 | Friesner Richard Director | Award | 8,141 | $0 |
| Jun 22, 2026 | OBEROI ARUN Director | Award | 8,141 | $0 |
| Jun 22, 2026 | van Kralingen Bridget A Director | Award | 8,141 | $0 |
| Jun 22, 2026 | Lynton Michael Director | Award | 8,141 | $0 |
| Jun 22, 2026 | Chodakewitz Jeffrey Director | Award | 8,141 | $0 |
| Jun 22, 2026 | Sender Gary Director | Award | 8,141 | $0 |
| Jun 22, 2026 | Thornberry Nancy Director | Award | 8,141 | $0 |
| Jun 22, 2026 | GINSBERG GARY L Director | Award | 8,141 | $0 |
| Apr 17, 2026 | Farid Ramy President & CEO | Option exercise 10b5-1 plan | 74,527 | $228.8K |
| Apr 17, 2026 | Farid Ramy President & CEO | Sale 10b5-1 plan | 43,000 | $524.9K |
| Apr 17, 2026 | Farid Ramy President & CEO | Option exercise 10b5-1 plan | 43,000 | $132.0K |
| Apr 16, 2026 | Jain Rachit EVP & CFO | Sale 10b5-1 plan | 844 | $10.8K |
| Apr 16, 2026 | Farid Ramy President & CEO | Sale 10b5-1 plan | 43,000 | $530.2K |
| Apr 16, 2026 | Farid Ramy President & CEO | Option exercise 10b5-1 plan | 43,000 | $132.0K |
| Mar 6, 2026 | Herman Jenny CAO | Sale 10b5-1 plan | 608 | $7.8K |
| Mar 5, 2026 | Herman Jenny CAO | Sale 10b5-1 plan | 775 | $10.0K |
| Mar 5, 2026 | Lorton Kenneth Patrick EVP, CTO & COO, Software | Sale 10b5-1 plan | 1,222 | $15.8K |
| Mar 5, 2026 | Tran Yvonne EVP, CLO & CPO | Sale 10b5-1 plan | 1,094 | $14.1K |
| Mar 5, 2026 | Jain Rachit EVP & CFO | Sale 10b5-1 plan | 1,631 | $21.0K |
| Mar 5, 2026 | Akinsanya Karen See Remarks | Sale 10b5-1 plan | 1,366 | $17.6K |
| Mar 5, 2026 | Farid Ramy President & CEO | Sale 10b5-1 plan | 3,661 | $47.2K |
| Mar 4, 2026 | Abel Robert Lorne See Remarks | Sale 10b5-1 plan | 1,300 | $16.7K |
| Mar 2, 2026 | Farid Ramy President & CEO | Sale 10b5-1 plan | 5,560 | $66.2K |
| Mar 2, 2026 | Akinsanya Karen See Remarks | Award 10b5-1 plan | 27,576 | $0 |
| Mar 2, 2026 | Akinsanya Karen See Remarks | Award 10b5-1 plan | 24,250 | $0 |
| Mar 2, 2026 | Akinsanya Karen See Remarks | Award 10b5-1 plan | 6,077 | $0 |
| Mar 2, 2026 | Akinsanya Karen See Remarks | Sale 10b5-1 plan | 2,206 | $26.5K |
| Mar 2, 2026 | Farid Ramy President & CEO | Award 10b5-1 plan | 56,250 | $0 |
| Mar 2, 2026 | Farid Ramy President & CEO | Award 10b5-1 plan | 13,604 | $0 |
| Mar 2, 2026 | Farid Ramy President & CEO | Award 10b5-1 plan | 48,259 | $0 |
| Mar 2, 2026 | Lorton Kenneth Patrick EVP, CTO & COO, Software | Award | 17,130 | $0 |
| Mar 2, 2026 | Lorton Kenneth Patrick EVP, CTO & COO, Software | Award | 20,682 | $0 |
| Mar 2, 2026 | Tran Yvonne EVP, CLO & CPO | Award | 17,130 | $0 |
| Mar 2, 2026 | Tran Yvonne EVP, CLO & CPO | Award | 13,788 | $0 |
| Mar 2, 2026 | Herman Jenny CAO | Award | 9,590 | $0 |
| Mar 2, 2026 | Abel Robert Lorne See Remarks | Award | 17,130 | $0 |
| Mar 2, 2026 | Abel Robert Lorne See Remarks | Award | 20,682 | $0 |
| Mar 2, 2026 | Friesner Richard Director | Option exercise | 160,527 | $492.8K |
| Mar 2, 2026 | Aklian Mannix Vartan See Remarks | Award | 17,130 | $0 |
| Mar 2, 2026 | Jain Rachit EVP & CFO | Award | 17,130 | $0 |
| Feb 10, 2026 | Herman Jenny CAO | Sale 10b5-1 plan | 752 | $10.4K |
| Feb 10, 2026 | Lorton Kenneth Patrick EVP, CTO & COO, Software | Sale 10b5-1 plan | 925 | $12.7K |
| Feb 10, 2026 | Tran Yvonne EVP, CLO & CPO | Sale 10b5-1 plan | 776 | $10.7K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Schrodinger, Inc.
Free account. Everything above stays public.
Write why you follow Schrodinger, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading